Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Insulet Corp
(NQ:
PODD
)
170.79
-10.29 (-5.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Insulet Corp
< Previous
1
2
3
4
5
6
Next >
What 8 Analyst Ratings Have To Say About Insulet
August 05, 2022
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:
Via
Benzinga
Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance
August 05, 2022
Via
Benzinga
Recap: Insulet Q2 Earnings
August 04, 2022
Insulet (NASDAQ:PODD) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Insulet missed estimated earnings by...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
July 11, 2022
Upgrades
Via
Benzinga
5 Analysts Have This to Say About Insulet
June 24, 2022
Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
4 Analysts Have This to Say About Insulet
June 07, 2022
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:
Via
Benzinga
7 Stocks to Buy That Could Make You a Millionaire
June 23, 2022
These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments.
Via
InvestorPlace
Comparing Fitbits To Medical Devices? This Company Says Things Aren't Even Close
June 16, 2022
The health and wellness industry focused on the well-being of the body, mind and spirit has captured the globe's attention. According to management consulting firm, Mckinsey & Co., the global wellness...
Via
Benzinga
Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks
May 31, 2022
The deal would have been transformative, but may have limited teamwork in the space.
Via
Investor's Business Daily
Looking Into Insulet's Return On Capital Employed
May 26, 2022
According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.
Via
Benzinga
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space
May 24, 2022
One analyst called the rumored deal "transformative," but says the timing is unfavorable.
Via
Investor's Business Daily
Expert Ratings for Insulet
May 06, 2022
Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings:
Via
Benzinga
Expert Ratings For Insulet
January 31, 2022
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:
Via
Benzinga
PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition
May 24, 2022
Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company.
Via
InvestorPlace
Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg
May 24, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
May 24, 2022
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!
Via
InvestorPlace
Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know
May 17, 2022
Citigroup has decided to maintain its Buy rating of Insulet (NASDAQ:PODD) and lower its price target from $350.00 to $310.00. Shares of Insulet are trading up 1.23% over the last 24 hours, at $199.34...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
May 17, 2022
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday.
Via
Benzinga
Recap: Insulet Q1 Earnings
May 05, 2022
Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by...
Via
Benzinga
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes
April 27, 2022
Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with...
Via
Benzinga
Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%
February 24, 2022
Insulet Corp's (NASDAQ: PODD) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million, exceeding the consensus of $301.06 million. The company...
Via
Benzinga
Recap: Insulet Q4 Earnings
February 23, 2022
Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet...
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
Earnings Scheduled For February 23, 2022
February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
February 03, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
February 02, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 28, 2022
Gainers Provention Bio (NASDAQ:PRVB) stoc...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...
Via
Benzinga
52 Biggest Movers From Friday
January 31, 2022
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.